Not available
Quote | Biogen Inc. (NASDAQ:BIIB)
Last: | $228.82 |
---|---|
Change Percent: | 0.03% |
Open: | $231.71 |
Close: | $228.82 |
High: | $233.17 |
Low: | $225.1 |
Volume: | 860,173 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Biogen Inc. (NASDAQ:BIIB)
2024-07-02 13:54:29 ET More on Eli Lilly 5 Reasons Eli Lilly Just Keeps Rising Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End Eli Lilly, Novo under pressure as Biden urges lower...
2024-07-02 12:18:09 ET Summary Today, we take a look at Cassava Sciences, Inc., which has a late-stage candidate targeting Alzheimer's, for the first time since late 2022. There has been a great deal of news flow around this controversial and high-risk/high-reward small-cap concer...
Message Board Posts | Biogen Inc. (NASDAQ:BIIB)
Subject | By | Source | When |
---|---|---|---|
Oops. Another HOD $10 | Lonewolf1 | investorshub | 03/29/2023 1:43:04 PM |
$BIIB Took a little short AH when it's | MiamiGent | investorshub | 03/23/2023 2:13:35 AM |
FDA Accepts Eisai's Filing of a Supplemental Biologics | Mr. Zen | investorshub | 03/06/2023 2:22:27 AM |
This board is about to light up! | Mr. Zen | investorshub | 03/06/2023 2:21:44 AM |
Well Biib and Esaly look to be joined | tredenwater2 | investorshub | 01/09/2023 11:15:02 PM |
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...